OGD2 Pharma SAS and Green Cross Lab Cell Corporation, a wholly-owned subsidiary of Green Cross Corporation, have entered a co-development agreement to develop cancer immunotherapy products targeting the OAcGD2 antigen.
Pursuant to the agreement, the two companies will conduct joint research, develop and commercialise the NK-cell therapeutics to target the OAcGD2 antigen using humanised antibody and chimeric antibody receptors (CAR), which fight against the solid tumours.
Go deeper with GlobalData
Regenerative medicine company ORIG3N has entered a partnership with Kangstem Biotech, a developer of stem-cell therapies, to further develop a personalised regenerative medicine.
According to the agreement, ORIG3N will utilise Kangstem Biotech’s induced neural stem cells (iNSC) in its disease-modelling platform to develop disease-modelling applications for the advancement of regenerative medicines.
Impax Labs has entered a definitive agreement with Teva Pharmaceuticals and affiliates of Allergan to expand and develop its genetic platform, research and development (R&D) and focus on long-term growth through improved business development strategies.
According to the agreement, Impax Labs will acquire a broad portfolio of generic products, which include solid oral, inhalable, injectable and topical dosages, for a purchase consideration of $586m.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSullivan & Cromwell LLP and McDermott Will & Emery LLP are acting as legal advisors to Impax Labs, while Greenhill & Co is acting as financial advisor and Kirkland & Ellis LLP is acting as legal advisor to Teva Pharma for the transaction.
Shanxi C&Y Pharmaceuticals has announced plans to raise $472.36m through the private placement of its shares.
The company plans to invest the funds in the acquisition of Shanxi Powerdone Pharmaceutics CO.Ltd.
F2G Ltd has raised gross proceeds of $60m in a venture financing round led by Sectoral Asset Management and co-led by Novo A/S, Aisling Capital and Brace Pharma Capital, Advent Life Sciences LLP, Novartis venture Funds, Sunstone Capital A/S and Merifin Capital.
The company plans to invest the funds in the further development of novel anti-fungal agents, pipeline products and product approvals.
Image: Impax Labs has entered a definitive agreement with Teva Pharmaceuticals and affiliates of Allergan. Photo: Courtesy of Raysonho.
